Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9456952 | 0.89 | MEN1 (0.36) | NAAAEPHX2 | |
| SCHEMBL3707695 | 0.88 | FFAR4 (0.46) | NAAAPPARGPPARA | |
| SCHEMBL9456879 | 0.84 | NAAA (0.39) | NAAA | |
| SCHEMBL10604986 | 0.84 | NAAA (0.38) | NAAAEPHX2 | |
| SCHEMBL9825825 | 0.83 | MEN1 (0.34) | — | |
| SCHEMBL9825662 | 0.83 | KDM4E (0.37) | PTGER2PTGER4PTGER3EPHX2 | |
| SCHEMBL31623378 | 0.82 | ALDH1A1 (0.33) | NAAA | |
| SCHEMBL31623372 | 0.82 | ALDH1A1 (0.33) | NAAA | |
| SCHEMBL31623366 | 0.82 | ALDH1A1 (0.33) | NAAA | |
| SCHEMBL11088435 | 0.82 | KMT2A (0.37) | NAAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637746-B1 | LEAVE-ON NON-SOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY]OCTADECANOIC ACID | UNILEVER PLC (GB) | 2016-11-30 | — | — | EP | disclosed |
| EP-2637746-B1 | LEAVE-ON NON-SOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY]OCTADECANOIC ACID | UNILEVER PLC (GB) | 2016-11-30 | — | — | EP | disclosed |
| EP-2637746-A2 | LEAVE-ON NON-SOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY]OCTADECANOIC ACID | Unilever PLC (GB) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062554-A2 | LEAVE-ON NON-SOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY] OCTADECANOIC ACID | UNILEVER PLC (GB) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062554-A2 | LEAVE-ON NON-SOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY] OCTADECANOIC ACID | UNILEVER PLC (GB) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122936-A1 | LEAVE-ON NONSOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY] OCTADECANOIC ACID | CONOPCO, INC., D/B/A UNILEVER (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122936-A1 | LEAVE-ON NONSOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY] OCTADECANOIC ACID | CONOPCO, INC., D/B/A UNILEVER (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122936-A1 | LEAVE-ON NONSOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY] OCTADECANOIC ACID | CONOPCO, INC., D/B/A UNILEVER (US) | 2012-05-17 | — | — | US | disclosed |
| US-6365637-B1 | SOLUBILIZING A COMPONENT OF AN AQUEOUS FORMULATION WHICH COMPRISES ADMIXING WITH THE COMPOSITION AN EFFECTIVE AMOUNT OF AT LEAST ONE ESTER OR AMIDE OF HYDROXYLATED CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122936-A1 | LEAVE-ON NONSOLID SKIN CONDITIONING COMPOSITIONS CONTAINING 12-[(12-HYDROXYOCTADECANOYL)OXY] OCTADECANOIC ACID | ALOX12, ALOX15, ALOX15B | NAAA 1937/4885PPARG 772/4885PTGER2 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.